Literature DB >> 10987373

Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients.

I Nordvik1, K M Myhr, H Nyland, K S Bjerve.   

Abstract

OBJECTIVE: To investigate whether supplementation with fish oil given together with dietary advice and vitamin supplementation influenced the clinical outcome in newly diagnosed multiple sclerosis (MS) patients.
MATERIAL AND METHODS: Sixteen consecutive, newly diagnosed patients with multiple sclerosis were recruited to an open intervention study. They were given dietary advice and supplemented with 0.9 g/day of long-chain marine fatty acids and vitamins. The patients were followed for 2 years with respect to dietary habits, blood parameters and neurological assessment including exacerbation rate.
RESULTS: There was a significant reduction in the mean annual exacerbation rate and the mean Expanded Disability Status Scale (EDSS) as compared to pre-study values. The plasma total phospholipid n-3 fatty acids increased and n-6 fatty acids decreased significantly.
CONCLUSIONS: The results suggest that fish oil supplementation given together with vitamins and dietary advice can improve clinical outcome in patients with newly diagnosed MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987373     DOI: 10.1034/j.1600-0404.2000.102003143.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  36 in total

Review 1.  Complementary and alternative medicine: is there a role in multiple sclerosis?

Authors:  Vijayshree Yadav; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

3.  Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis.

Authors:  S J van Rensburg; M J Kotze; D Hon; P Haug; J Kuyler; M Hendricks; J Botha; F C V Potocnik; T Matsha; R T Erasmus
Journal:  Metab Brain Dis       Date:  2006-05-26       Impact factor: 3.584

4.  Saturated long-chain fatty acids activate inflammatory signaling in astrocytes.

Authors:  Sunita Gupta; Alecia G Knight; Shruti Gupta; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2012-02-06       Impact factor: 5.372

Review 5.  The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review.

Authors:  Leah J Mische; Ellen M Mowry
Journal:  Curr Treat Options Neurol       Date:  2018-03-17       Impact factor: 3.598

6.  The Level of Testosterone, Vitamin D, and Irregular Menstruation More Important than Omega-3 in Non-Symptomatic Women Will Define the Fate of Multiple Scleroses in Future.

Authors:  Shima Tavakol; Sahar Shakibapour; Sepideh Arbabi Bidgoli
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

7.  Exercise contributes to the effects of DHA dietary supplementation by acting on membrane-related synaptic systems.

Authors:  Gabriela Chytrova; Zhe Ying; Fernando Gomez-Pinilla
Journal:  Brain Res       Date:  2009-05-13       Impact factor: 3.252

8.  Omega-3 fatty acids and multiple sclerosis: relationship to depression.

Authors:  Robin L Aupperle; Douglas R Denney; Sharon G Lynch; Susan E Carlson; Debra K Sullivan
Journal:  J Behav Med       Date:  2008-04

9.  Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.

Authors:  Athena Kalyvas; Constantinos Baskakis; Victoria Magrioti; Violetta Constantinou-Kokotou; Daren Stephens; Rubèn López-Vales; Jian-Qiang Lu; V Wee Yong; Edward A Dennis; George Kokotos; Samuel David
Journal:  Brain       Date:  2009-02-13       Impact factor: 13.501

10.  Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study.

Authors:  Geeta S M Ramsaransing; Sanne A Mellema; Jacques De Keyser
Journal:  Nutr J       Date:  2009-08-10       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.